ALX Oncology reports Q4 net loss $30.7M; cash $282.9M; clinical milestones ahead

ALX ONCOLOGY HOLDINGS INC

Q4 2022 GAAP net loss $30.7M ($0.75/sh) vs $28.4M ($0.70/sh) in Q4 2021.
Full year 2022 GAAP net loss $123.5M ($3.03/sh) vs $83.5M ($2.07/sh) in 2021.
Cash & investments $282.9M; $100M loan facility (drew $10M); runway through mid-2025.
Key milestones: ASPEN-06 (gastric) and ASPEN-02 (MDS) data H2 2023; ASPEN-07 (UC) dosed Feb 2023.
Board strengthened with Scott Garland; IND for ALTA-002 (Tallac) expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

ALX ONCOLOGY HOLDINGS INC reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-23-006999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.